OBJECTIVE: To evaluate the validity of newly developed pain behavior measures in two murine models of inflammatory arthritis and to determine the ability of these measures to evaluate the analgesic effectiveness of intra-articular (IA) botulinum toxin type A (BoNT/A) for treatment of arthritis pain. DESIGN: Acute inflammatory arthritis was produced in adult female mice by IA injection of carrageenan and chronic inflammatory arthritis by IA injection of CFA. The presence of arthritis was confirmed by the presence of swelling and erythema. A menu of pain behavior measures was devised for quantitating pain in these models including tenderness, and spontaneous nocturnal wheel running. Toxicity due to neurotoxin was measured as gross limb weakness and impaired functional ability during wheel running. RESULTS: Tenderness measures and spontaneous nocturnal wheel-running are valid measures of arthritis pain and are sensitive to the effects of analgesia. Narcotic analgesics are effective, but in fully analgesic doses impair wheel-running. IA BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. High doses can produce local limb muscle weakness, which impairs wheel-running function. Doses of botulinum toxin that are not toxic retain their analgesic function. CONCLUSIONS: Tenderness and spontaneous pain behavior measures are valid and sensitive for the measurement of pain and analgesia in murine models of inflammatory arthritis. Effective narcotic analgesia produces a decline in function in mice similar to that seen in humans. IA neurotoxin is a promising therapy for chronic inflammatory arthritis but may not be effective for acute arthritis pain.
OBJECTIVE: To evaluate the validity of newly developed pain behavior measures in two murine models of inflammatory arthritis and to determine the ability of these measures to evaluate the analgesic effectiveness of intra-articular (IA) botulinum toxin type A (BoNT/A) for treatment of arthritis pain. DESIGN: Acute inflammatory arthritis was produced in adult female mice by IA injection of carrageenan and chronic inflammatory arthritis by IA injection of CFA. The presence of arthritis was confirmed by the presence of swelling and erythema. A menu of pain behavior measures was devised for quantitating pain in these models including tenderness, and spontaneous nocturnal wheel running. Toxicity due to neurotoxin was measured as gross limb weakness and impaired functional ability during wheel running. RESULTS: Tenderness measures and spontaneous nocturnal wheel-running are valid measures of arthritis pain and are sensitive to the effects of analgesia. Narcotic analgesics are effective, but in fully analgesic doses impair wheel-running. IA BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. High doses can produce local limb muscle weakness, which impairs wheel-running function. Doses of botulinum toxin that are not toxic retain their analgesic function. CONCLUSIONS: Tenderness and spontaneous pain behavior measures are valid and sensitive for the measurement of pain and analgesia in murine models of inflammatory arthritis. Effective narcotic analgesia produces a decline in function in mice similar to that seen in humans. IA neurotoxin is a promising therapy for chronic inflammatory arthritis but may not be effective for acute arthritis pain.
Authors: Ki Yeon Yoo; Hee Su Lee; Young Kyung Cho; You Sun Lim; Yi Seul Kim; Jung Hoi Koo; Se Jin Yoon; Jung Hwan Lee; Ki Hyo Jang; Sun Hong Song Journal: Neurotox Res Date: 2013-12-12 Impact factor: 3.911
Authors: Joseph Bert; Maren L Mahowald; Sandra Frizelle; Christopher W Dorman; Sonia C Funkenbusch; Hollis E Krug Journal: Intern Med Rev (Wash D C) Date: 2016
Authors: Mohammed S A Suhail; Christina Christianson; Fred Koehrn; Shelle A Malkmus; William Mitchell; Maripat Corr; Tony L Yaksh Journal: Neurocomputing Date: 2011-12-31 Impact factor: 5.719
Authors: Ryan A Whitehead; Nicholas L Lam; Melody S Sun; Joshua Sanchez; Shahani Noor; Arden G Vanderwall; Timothy R Petersen; Hugh B Martin; Erin D Milligan Journal: Anesth Analg Date: 2017-01 Impact factor: 5.108